Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure.

ABSTRACT:

Background

Nucleos(t)ide analogues (NUCs) treatment can reduce the risk of hepatocellular carcinoma (HCC) development and recurrence in chronic hepatitis B (CHB) patients. However, the risk of recurrence in CHB patients who develop HCC despite NUC treatment remains unclear.

Methods

167 consecutive CHB patients receiving curative resection for HCC with NUC therapy after surgery were retrospectively enrolled. Thirty-eight patients who developed HCC despite NUC therapy for more than 1 year were defined as secondary prevention failure. The other 129 patients started NUC therapy after surgery. Factors associated with recurrence-free survival (RFS) and overall survival (OS) were evaluated.

Results

The 5-year RFS and OS rates were 44.7% and 77.3%, respectively. Sex, BMI, BCL

SUBMITTER: Lee IC 

PROVIDER: S-EPMC5703552 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature